Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
Patents for C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
10/2005
10/25/2005US6958346 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein
10/25/2005US6958338 E.g., 5-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-indole; partial agonists or antagonist at the dopamine D4 receptors; psychoses, schizophrenia, cognition activators; attention deficit disorder; dyskinesia; side effects reduction
10/25/2005US6958332 Treating an interleukin-12 overproduction-related disorder; treating rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus
10/25/2005US6958328 5H-indeno(1,2-b)pyridine-3-carboxylic acid,4-phenyl-2-amino-5-oxo-, ethyl ester; adenosine receptor antagonists, phosphodiesterase inhibitors; neurodegenerative disorders, AIDS; antiinflammatory agent
10/25/2005CA2304974C 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
10/25/2005CA2261725C Piperidine and piperazine derivatives and their use as muscarinic antagonists
10/25/2005CA2110454C 1,5,7-trisubstituted indoline compounds for the treatment of dysuria
10/25/2005CA2059882C Sulfonylureas
10/20/2005WO2005097791A1 Inhibitors of iap
10/20/2005WO2005097784A1 Phenylthioacetic acid derivatives and use thereof
10/20/2005WO2005097779A1 Diarylamine derivatives as calcium channel blockers
10/20/2005WO2005097774A1 Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
10/20/2005WO2005097770A1 Novel hydroxamates as therapeutic agents
10/20/2005WO2005097758A1 Certain triazole-based compounds, compositions, and uses thereof
10/20/2005WO2005097750A1 Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)
10/20/2005WO2005097746A2 2-propene-1-ones as hsp 70 inducers
10/20/2005WO2005097740A1 Histamine h3 receptor agents, preparation and therapeutic uses
10/20/2005WO2005097137A2 Advanced quinazoline based protein kinase inhibitors
10/20/2005WO2005097136A1 Biaryl substituted pyrazinones as sodium channel blockers
10/20/2005WO2005097134A2 Quinazoline based protein kinase inhibitors
10/20/2005WO2005085236A3 Caspase inhibitors and uses thereof
10/20/2005WO2005070891A3 Compounds and methods of use
10/20/2005WO2005061450A3 Hiv protease inhibiting sulfonamides
10/20/2005WO2005055715A3 Insecticidal n-(heteroarylalkyl) alkanediamine derivatives
10/20/2005WO2005046590A3 Methods for synthesizing quinolinone compounds
10/20/2005WO2005030794B1 Hemiasterlin derivatives and uses thereof
10/20/2005WO2005012320A3 Novel lincomycin derivatives possessing antimicrobial activity
10/20/2005WO2004071460A3 Cyclic derivatives as modulators of chemokine receptor activity
10/20/2005US20050234247 New effector conjugates, process for their production and their pharmaceutical use
10/20/2005US20050234117 and geranylgeranyltransferase inhibitor; 3-chloromethyl-4-cyanobenzyl-5 methyl triazole; antitumor agents; prevent membrane attachment of protein p21ras and block aberrant growth of ras-transformed tumors; capable to inhibit prenylation of Ras proteins, both at enzymatic and cellular level
10/20/2005US20050234109 to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine
10/20/2005US20050234083 Diamino-pyrimidines and their use as angiogenesis inhibitors
10/20/2005US20050234082 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
10/20/2005US20050234062 Such as 2-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-2H-acetamide; phosphodiesterase inhibitors; for treatment of respiratory disorders
10/20/2005US20050234059 4-(5-Methyl-2-phenyl-pyrimidin-4-yl)-1H-pyrrole-2 carboxylic acid (2-hydroxy-1-(S)-phenyl-ethyl)-amide; Mitogen-activated protein kinase inhibitor; anticarcinogenic, antiinflammatory agent,neurodegenerative disorders, restenosis, antidiabetic, antiallergen, and cardiovascular disease
10/20/2005US20050234057 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof
10/20/2005US20050234049 Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
10/20/2005US20050234048 substituted 4,5-dihydro-1H-benzo[b][1,4]-diazepin-2-one; amidation of a substituted monoprotected 1,2-diaminobenzene with an ester, deprotecting, cyclization; chronic neurological disorders, psychosis, schizophrenia, Alzheimer's disease
10/20/2005US20050234047 Respiratory syncytial virus replication inhibitors
10/20/2005US20050234045 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
10/20/2005US20050234044 Cyclic amine derivatives and methods of use
10/20/2005US20050234042 Organic compounds
10/20/2005US20050234041 Substituted 1-benzazepines and derivatives thereof
10/20/2005US20050234030 Modulators of CRTH2, COX-2 and FAAH
10/20/2005US20050233987 B-cell chronic lymphocytic leukemia, splenic marginal zone lymphoma (SMZL), mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, and Waldenstrom syndrome
10/20/2005US20050233979 Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, (S,S)-3-[2-(3-Acetylamino-2-oxo-2H-pyridin-1-yl)-butyrylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid
10/20/2005CA2567574A1 Benzotriazine inhibitors of kinases
10/20/2005CA2562371A1 Diarylamine derivatives as calcium channel blockers
10/20/2005CA2562140A1 Phenylthioacetic acid derivatives and use thereof
10/20/2005CA2561967A1 Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
10/20/2005CA2561532A1 Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
10/20/2005CA2561280A1 Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)
10/20/2005CA2560954A1 Certain triazole-based compounds, compositions, and uses thereof
10/20/2005CA2560796A1 Biaryl substituted pyrazinones as sodium channel blockers
10/20/2005CA2560162A1 Inhibitors of iap
10/19/2005EP1586572A1 Fused pyrazolyls as anti-cancer drugs
10/19/2005EP1586565A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
10/19/2005EP1586561A1 Bicyclic aromatic sulfinyl derivatives
10/19/2005EP1586559A1 Biaryl-methanethio-, -sulphinyl- and sulphonyl derivatives
10/19/2005EP1586558A2 Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors
10/19/2005EP1585743A1 2-(1h-indazol-6-ylamino)- benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
10/19/2005EP1585742A1 Substituted benzoyl derivatives uses as herbicides
10/19/2005EP1585735A1 Hydroxamid acid derivatives as histone deacetylase (hdac) inhibitors
10/19/2005EP1585728A1 Imino acid derivatives for use as inhibitors of matrix metalloproteinases
10/19/2005EP1585727A1 Indoles useful in the treatment of androgen-receptor related diseases
10/19/2005EP1585521A2 Derivatives of aryl-quinazoline/aryl-2amino-phenyl methanone which promote the release of parathyroid hormone
10/19/2005EP1585517A1 Use of substituted 2-phenylbenzimidazoles as medicaments
10/19/2005EP1463714A4 Vanilloid receptor ligands and their use in treatments
10/19/2005EP1423373B1 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
10/19/2005EP1255740B1 Substituted arylpyrazines
10/19/2005EP1240142B1 New modulators of dopamine neurotransmission
10/19/2005EP1102752B1 Succinoylamino lactams as inhibitors of a beta protein production
10/19/2005EP0995745B1 Heat shock factor activity inhibitors
10/19/2005EP0966446B1 Bicyclic inhibitors of protein farnesyl transferase
10/19/2005CN1684955A Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
10/19/2005CN1683343A Novel method of synthesising 1, 3, 4, 5-tetrahydro-2H-3-benzazepin-2-one derivatives and use thereof in the synthesis of ivabradine and the salts thereof for addition to a pharmaceutically acceptable aci
10/19/2005CN1683342A New process for the synthesis of 1, 3-dihydro-2H-3-benzazepin-2-one compounds, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
10/19/2005CN1223591C Piperazine oxime derivatives having Nk-1 receptor antagonistic activity
10/19/2005CN1223348C N-(aryloxy group alkyl) heteroaromatic guadine and heteroaromatic guazine used as medicines
10/18/2005US6956988 Optical interleaver
10/18/2005US6956121 Dealkylation, neutralization, crystallization; antidepressants, psychological disorders
10/18/2005US6956055 Substituted γ-lactone compounds as NMDA-antagonists
10/18/2005US6956052 treatment of cancer and inflammation-associated disorders, such as arthritis; for example,1-[4-(aminosulfonyl)phenyl]-8-{[(trifluoromethyl)sulfonyl]amino}-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
10/18/2005US6956033 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient
10/18/2005CA2295063C Indole compounds as anti-inflammatory/analgesic agents
10/18/2005CA2294171C N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
10/18/2005CA2190129C Therapeutic phenoxyalkylpyridazines and intermediates therefor
10/18/2005CA2125730C Novel sulfonylamino pyrimidines
10/18/2005CA2104399C Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
10/13/2005WO2005095409A2 Tetrahydroquinoline derivatives and a process for preparing the same
10/13/2005WO2005095385A1 Process for the preparation of tryptase inhibitors
10/13/2005WO2005095384A1 Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists
10/13/2005WO2005095380A1 Cyclic amine compound and pest control agent
10/13/2005WO2005095359A1 Diaminopyrimidines as p2x3 and p2x2/3 antagonists
10/13/2005WO2005095357A2 Pyrimidine derivatives and methods of treatment related to the use thereof
10/13/2005WO2005095356A1 Agent for generating heat or singlet oxygen and composition for cancer treatment each comprising organic peroxide or chemiluminescent compound
10/13/2005WO2005095353A1 Tetrahydro-indazole cannabinoid modulators
10/13/2005WO2005095350A1 Pyrazole compounds and uses related thereto
10/13/2005WO2005095348A2 Pyrazole-amine compounds for the treatment of neurodegenerative disorders
10/13/2005WO2005095346A1 3-((hetero)arylsulfonyl)-8-` (aminoalkyl)oxy!quinolines as 5-ht6 receptor antagonists for the treatment of cns disorders
1 ... 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 ... 694